Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0024141 (systemic lupus erythematosus)
 44,322 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

We have found a new permeability factor in serum of patients with systemic lupus erythematosus. It is non-dialyzable, heat stable, and long acting as compared to histamine or bradykinin which is short acting. It has no esterolytic nor smooth muscle contracting activities. It is not inhibited by anti-histamine drugs, soy bean trypsin inhibitor, DFP or Cl esterase inhibitor. It is independent of the kallikrein system. It has the common antigenicity with IgG Fc fragments. Its approximate molecular weight is about 55,000. So we tentatively call this permeability factor IgG-PF. Intravenous injections of HGG-anti-HGG immune complex, which has been formed by antigen-antibody reactions in 20 times antigen excess, into rats resulted in no immune complex nephritis. However, intravenous injections of HGG-anti-HGG immune complex with IgG-PF resulted in immune complex nephritis in rats. The above immune complex nephritis was inhibited by administrations of sulfapyridine but not by administrations of anti-histamine. These results indicate that IgG-PF plays some roles in the mechanism of immune complex nephritis.
 ...
PMID:The presence of new permeability factor in serum of patients with systemic lupus erythematosus and its significance. 63 92